TY  - GEN
AU  - Jiménez-Ubieto, Ana
AU  - Martín-Muñoz, Alejandro
AU  - Poza, María
AU  - Dorado, Sara
AU  - García-Ortiz, Almudena
AU  - Revilla, Enrique
AU  - Sarandeses, Pilar
AU  - Ruiz-Heredia, Yanira
AU  - Baumann, Tycho
AU  - Rodríguez, Antonia
AU  - Calbacho, María
AU  - Sánchez, Pilar Martínez
AU  - Pina, José María Sánchez
AU  - García-Sancho, Alejandro Martín
AU  - Figaredo, Gloria
AU  - Rufián, Laura
AU  - Rodríguez, Margarita
AU  - Carneros, Laura
AU  - Martínez-Laperche, Carolina
AU  - Bastos-Oreiro, Mariana
AU  - Wang, Chongwu
AU  - Cedena, María-Teresa
AU  - Rapado, Inmaculada
AU  - de Toledo, Paula
AU  - Gallardo, Miguel
AU  - Valeri, Antonio
AU  - Ayala, Rosa
AU  - Martinez-Lopez, Joaquin
AU  - Barrio, Santiago
PY  - 2023
DO  - 10.3389/fimmu.2023.1188818
UR  - https://hdl.handle.net/20.500.12105/23125
AB  - BACKGROUND: CART therapy has produced a paradigm shift in the treatment of relapsing FL patients. Strategies to optimize disease surveillance after these therapies are increasingly necessary. This study explores the potential value of ctDNA monitoring...
LA  - eng
PB  - Frontiers Media
KW  - Circulating Tumor DNA
KW  - Receptors, Chimeric Antigen
KW  - Lymphoma, Follicular
KW  - Humans
KW  - Female
KW  - Immunotherapy, Adoptive
KW  - Positron Emission Tomography Computed Tomography
KW  - Neoplasm Recurrence, Local
TI  - Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
TY  - research article
ER  -